Clinical trial
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
NCT00449397 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00449397 |
|---|---|
| Title | Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis |
| Official title | A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psychosis |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate |
| Enrollment | 150 |
| Start date | Jul 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Mar 20, 2007 |
| Last update posted | Jan 27, 2011 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: